Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
177 hedge funds and large institutions have $375M invested in Antares Pharma, Inc. in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 56 increasing their positions, 57 reducing their positions, and 9 closing their positions.
589% more call options, than puts
Call options by funds: $868K | Put options by funds: $126K
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
23% more capital invested
Capital invested by funds: $305M → $375M (+$69.7M)
9% more funds holding
Funds holding: 162 → 177 (+15)
2% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$6.91M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$4.89M |
| 3 |
Amundi
Paris,
France
|
+$3.46M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.02M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$5.01M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.98M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$757K |
| 4 |
Barclays
London,
United Kingdom
|
-$674K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$607K |
ATRS Hedge Fund Activity: Q1 2022 in Review
177 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2022, worth a combined $375M — up 23% from $305M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ATRS positions and 9 closed out — a net gain of 17 holders — while 56 added to existing stakes and 57 trimmed.
The largest buyer was Russell Investments Group, adding an estimated $6.91M. The largest seller was Magnetar Financial, cutting an estimated $5.01M.
- 177 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2022, up from 162 in Q4 2021.
- Funds reported $375M of Antares Pharma, Inc. stock for Q1 2022, up 23% quarter-over-quarter.
- 26 funds opened new Antares Pharma, Inc. positions in Q1 2022 and 9 closed out, a net change of +17 holders.
- The largest Antares Pharma, Inc. buyer in Q1 2022 was Russell Investments Group, an estimated $6.91M added.
- The largest Antares Pharma, Inc. seller in Q1 2022 was Magnetar Financial, an estimated $5.01M sold.
Based on aggregated 13F filings for Q1 2022.